Literature DB >> 25387129

Putative transmembrane domain 6 of the human organic anion transporting polypeptide 1A2 (OATP1A2) influences transporter substrate binding, protein trafficking, and quality control.

Ting Chan1, Jian Zheng, Ling Zhu, Thomas Grewal, Michael Murray, Fanfan Zhou.   

Abstract

The human organic anion transporting polypeptides (OATPs) are a family of important membrane proteins that mediate the cellular influx of various anionic substances including clinically important drugs. Transmembrane domain 6 (TM6) is a distinctive consensus "signature" common to all OATPs. Two naturally occurring variants were previously identified in TM6 of the important transporter OATP1A2; these variants may be associated with suboptimal drug influx into cells. Because of the potential importance of TM6 in drug efficacy, this study investigated its role in substrate uptake by OATP1A2. Single amino acid replacements were introduced into TM6 of OATP1A2 (residues 245-266) by alanine-scanning mutagenesis. Uptake assays, biotinylation and immunoblotting were used to assess the function and expression of OATP1A2 and its mutants after overexpression in HEK293 cells. Uptake of the model substrates estrone-3-sulfate and methotrexate by OATP1A2 mutants carrying amino acid replacements within the TM6 subregions of 245-248 and 261-266 was impaired, while transport function was largely retained by other mutants. From kinetic, biotinylation, and immunoblot analysis the diminished function of the 245-248 and 261-266 mutants was due primarily to decreased plasma membrane and total cell expression and also to a less extent, impacted by altered substrate binding. Further experiments with proteasomal or lysosomal inhibitors were consistent with impaired maturation and impaired plasma membrane insertion of several mutants of OATP1A2 within the subregions of 245-248 and 261-266. In addition, the finding that total cellular expression, but not plasma membrane expression, was less impaired for the W245A and W246A mutants suggests that these two TM6 residues might be involved in membrane targeting of OATP1A2. These findings implicate the TM6 subregions of 245-248 and 261-266 in substrate binding, protein trafficking, and quality control of OATP1A2.

Entities:  

Keywords:  membrane trafficking; organic anion transporting polypeptide 1A2; protein quality control; transporter substrate binding

Mesh:

Substances:

Year:  2014        PMID: 25387129     DOI: 10.1021/mp500459b

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  5 in total

1.  Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.

Authors:  Xiaoxi Lu; Ting Chan; Chenghao Xu; Ling Zhu; Qi Tony Zhou; Kade D Roberts; Hak-Kim Chan; Jian Li; Fanfan Zhou
Journal:  J Antimicrob Chemother       Date:  2015-10-22       Impact factor: 5.790

Review 2.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 3.  Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides.

Authors:  Wooin Lee; Jeong-Min Ha; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2020-10-13       Impact factor: 5.157

4.  The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice.

Authors:  Chenghao Xu; Ling Zhu; Ting Chan; Xiaoxi Lu; Weiyong Shen; Mark C Gillies; Fanfan Zhou
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

5.  Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver.

Authors:  Tatsuya Taniguchi; Alana Zanetti-Yabur; Pijun Wang; Mykhaylo Usyk; Robert D Burk; Allan W Wolkoff
Journal:  Hepatol Commun       Date:  2020-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.